Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

ClinicalTrials.gov ID: NCT02858726

Public ClinicalTrials.gov record NCT02858726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Two-Part, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Study identification

NCT ID
NCT02858726
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Cara Therapeutics, Inc.
Industry
Enrollment
226 participants

Conditions and interventions

Interventions

  • CR845 0.5 mcg/kg Drug
  • CR845 1 mcg/kg Drug
  • CR845 1.5mcg/kg Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2016
Primary completion
Mar 13, 2017
Completion
Mar 13, 2017
Last update posted
Jul 28, 2020

2016 – 2017

United States locations

U.S. sites
29
U.S. states
16
U.S. cities
26
Facility City State ZIP Site status
Cara Therapeutics Investigator Site Phoenix Arizona 85035
Cara Therapeutics Study Site Pine Bluff Arkansas 71603
Cara Therapeutics Investigator Site Long Beach California 90806
Cara Therapeutics Study Site Northridge California 91324
Cara Therapeutics Study Site Whittier California 90603
Cara Therapeutics Study Site Denver Colorado 80218
Cara Therapeutics Study Site Hollywood Florida 33024
Cara Therapeutics Study Site Tampa Florida 33614
Cara Therapeutics Study Site Winter Park Florida 32789
Cara Therapeutics Study Site Augusta Georgia 30909
Cara Therapeutics Study Site Meridian Idaho 83642
Cara Therapetics Study Site Creve Coeur Missouri 63141
Cara Therapeutics Study Site Kansas City Missouri 64111
Cara Therapeutics Study Site Kansas City Missouri 64131
Cara Therapeutics Study Site Omaha Nebraska 68124
Cara Therapetics Investigator Site Albuquerque New Mexico 87109
Cara Therapeutics Study Site Gallup New Mexico 87301
Cara Therapeutics Study Site College Point New York 11385
Cara Therapeutics Investigator Site Mineola New York 11501
Cara Therapeutics Investigator Site Wilmington North Carolina 28401
Cara Therapeutics Study Site Winston-Salem North Carolina 27103
Cara Therapeutics Study Site Bethlehem Pennsylvania 18017
Cara Therapeutics Investigator Site Philadelphia Pennsylvania 19140
Cara Therapeutics Study Site Chattanooga Tennessee 37408
Cara Therapetics Study Site Knoxville Tennessee 37920
Cara Therapeutics Study Site San Antonio Texas 78221
Cara Therapeutics Study Site San Antonio Texas 78229
Cara Therapeutics Study Site San Antonio Texas 78251
Cara Therapeutics Study Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02858726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 28, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02858726 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →